Skills Alliance’s Post

Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that their acumen with gene editing will enable them to make therapies that were impossible to conceive of just a few years ago, and they're both aiming for the same disease markets. https://lnkd.in/dfNWvrXk

Thoughts on this? >> BIX Korea 2024: Promise of mRNA technology for cell and gene therapy - BioWorld Online >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #competitivemarketing #biotech #healthcare #pharmaceutical

Precision's Anshul Mangal weighs in on what to expect in 2024 regarding biopharma manufacturing and supply-related issues in this Scrip Asks Part 3 series. "Cell and gene therapies will continue to dominate the innovative clinical pipeline with the largest number of treatments in clinical trials (589 gene therapies and 568 cell therapies). The recent historic landmark of the first CRISPR technology gaining regulatory approval signals confidence in this approach. Additionally, as the adoption of radioligand therapy increases, it continues to show profound potential. One of the most promising aspects of radioligand therapy lies in the potential to create unique combinations of radioactive atoms and targeting molecules tailored to specific tumor types." Read the article here (subscription required): https://hubs.ly/Q02jhS1j0 #precisionmedicine #biopharma #clinicaltrials

Precision's Anshul Mangal weighs in on what to expect in 2024 regarding biopharma manufacturing and supply-related issues in this Scrip Asks Part 3 series. "Cell and gene therapies will continue to dominate the innovative clinical pipeline with the largest number of treatments in clinical trials (589 gene therapies and 568 cell therapies). The recent historic landmark of the first CRISPR technology gaining regulatory approval signals confidence in this approach. Additionally, as the adoption of radioligand therapy increases, it continues to show profound potential. One of the most promising aspects of radioligand therapy lies in the potential to create unique combinations of radioactive atoms and targeting molecules tailored to specific tumor types." Read the article here (subscription required): https://hubs.ly/Q02jkmfX0 #precisionmedicine #biopharma #clinicaltrials

One month to go before our round table discussion debating cell and gene vs. small molecule therapies. Really looking forward to advocating for biotech approaches for curing disease. We are living in an exciting time with medical breakthroughs seemingly every day. If you would like to join us, take a look at the below links. #cellandgenetherapy #pharmaceuticals #biotech #ipstrategy

Thoughts on this? >> Indian President Droupadi Murmu launches first homegrown gene therapy for cancer - WION >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #pharmaceutical #competitivemarketing

Thoughts on this? >> BIX Korea 2024: Promise of mRNA technology for cell and gene therapy - BioWorld Online >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #pharma #biotech #healthcare

🌐rizochem.com | rizochem.ae Vertex Announces Price of Sickle Cell Disease Gene Therapy Vertex Pharmaceuticals and its partner CRISPR Therapeutics announced that their sickle cell disease gene therapy, Casgevy, will be available at a list price of $2.2 million in the United States. This price tag has sparked debate about the affordability of gene therapies, with some arguing that it is too expensive and will limit access to patients who need it. #pharma #pharmaceutical #health #medicine #clinicaltrials #biotechnology

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Syncona buys gene therapy company; Oryzon’s €45M financing agreement; InDex scraps PhIII drug: Syncona scoops up Freeline: British life sciences investor Syncona said Wednesday it agreed to buy gene therapy maker Freeline Therapeutics through a new portfolio company. Syncona already owns the majority of Nasdaq-listed Freeline, and it made its acquisition intentions known last month. — Kyle LaHucik Oryzon Genomics secures €45M in financing: The company announced Tuesday that it signed a convertible bond agreement with the Swiss investment firm Nice & Green for €45 million, made up of several tranches of €5 million each. “In this unpredictable market situation, we are excited to have secured this financial support,” Oryzon CEO Carlos Buesa said in a news release. Oryzon expects topline data early next year for a Phase IIb study of its borderline personality disorder treatment. — Jaimy Lee Swedish pharma scraps PhIII drug: InDex Pharmaceuticals said Tuesday that it discontinued a late-stage program for cobitolimod, its experimental ulcerative colitis therapy after a data monitoring committee said the treatment was unlikely to meet the primary endpoint. — Jaimy Lee SK bioscience and Hilleman Laboratories said Wednesday they plan to develop a second-generation Zaire Ebola virus vaccine. Financial terms of the deal were not disclosed. — Jaimy Lee #lucidquest #genetherapy #celltherapy

Learn how Gyros can help you switch from manual Elisa assays to get 10X faster results. It's not just about the speed but also about reducing the time and materials impacting your bottom line